Quassinoids are derivatives degraded from triterpenoids that are widely distributed in the Simaroubaceae family. These metabolites exhibit different bioactivities such as anti-inflammation, antiparasitic and antimalarial. In the last years, several quassinoids isolated from Simaroubacea family have been demonstrated to possess anticancer activities. However, the toxicity of quassinoids to healthy cells has limited their development into therapeutic agents. To overcome these drawbacks, a promising and innovative approach will explore targeted quassinoids delivery systems to minimize potential side effects. Simalikalactone D (SKD), a quassinoid, was isolated by our research group and showed potent in vitro cytotoxicity with IC50s of 58 nM to 65 nM on breast cancer cell lines. However, SKD showed a similar effect on non-tumoral mammary epithelial cells (Mendez et al., 2020). Therefore, our goal is to characterize new interesting quassinoids and prepare a lipid nanoformulation of SKD to reduce potential toxicity. For this purpose, the freeze-drying method will be used to produce stable liposomes. SKD and new quassinoids will be isolated by chromatography and characterized by NMR.

Further studies on Quassinoids: Nanocarrier design and characterization of SKD derivatives

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.